Novobiocin
From Wikipedia, the free encyclopedia
 |
|
|
Novobiocin
|
|
| Systematic (IUPAC) name | |
| 4-Hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)benzamido]-8-methylcoumarin-7-yl 3-O-carbamoyl-5,5-di-C-methyl-α-l-lyxofuranoside | |
| Identifiers | |
| CAS number | 303-81-1 |
| ATC code | ?[1] {{}} |
| PubChem | 7526 |
| DrugBank | APRD00694 |
| Chemical data | |
| Formula | C31H36N2O11 |
| Mol. weight | 612.624 |
| Pharmacokinetic data | |
| Bioavailability | negligible oral bioavailability |
| Metabolism | excreted unchanged |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | intravenous |
Novobiocin is a coumarin antibiotic used to treat Staphylococcus epidermidis. It acts by inhibiting DNA gyrase, an enzyme that mediates the supercoiling of DNA. DNA gyrase has no mammalian equivalent.
Novobiocin is an aromatic ether compound.
 |
This bacteria-related article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
